Show an ad over header. AMP

I am the FIRST

Should anyone be able to get a COVID-19 vaccine booster? The ethics says no

The Biden administration is expected to soon recommendbooster doses of the COVID-19 vaccine for everyone, but that decision fails fundamental ethics tests, according to interviews with physicians and medical ethicists.

Why it matters: There is still a global shortage of vaccines. Even amid concerns of the spreading Delta variant, experts say it's difficult to justify a third dose for relatively healthy people in the U.S. when many others haven't gotten their first.


Driving the news: The booster shots would likely be administered around eight months after someone received their two mRNA vaccine doses from Pfizer or Moderna their single Johnson & Johnson shot, according to initial reports.

  • An independent CDC panel and the FDA have not signed off on this plan yet.
  • This possible plan comes a week after the CDC and FDA formally recommended the nation's 9 million immunocompromised people get a third dose of the Pfizer or Moderna vaccine.
  • Data have indicated for months that the immunocompromised, especially organ transplant patients, were less protected from the two-shot course.
  • A third dose for the immunocompromised is reasonable, ethicists say, because three doses should have been their default regimen, and it will give a boost in protection to a group that is more likely to end up in the hospital from COVID-19.

Yes, but: "Once you get to anybody who wants to get a third dose, then I think other people in other countries start to have a rightful basis for complaint," said Govind Persad, a health policy and ethics professor at the University of Denver.

  • The vaccines appear to be less effective as time goes on, but there's no rigorous data quantifying that yet.
  • The vaccines still prevent almost all instances of death and hospitalization from severe disease.
  • The risk of vaccinated people with normal immune systems passing the Delta variant on to other vaccinated people also appears very low.
  • Meanwhile, the coronavirus is raging in low-vaccinated places like Botswana, Cuba and Iran, which "translates into disparities in mortality rates from COVID-19," ethicists wrote in JAMA last week.

"We have people in sizable numbers who have zero protection," said Ruth Faden, a bioethicist at Johns Hopkins University and member of the World Health Organization's panel that advised against boosters except for high-risk people. "The global ethics case is clear."

Reality check: The U.S. has bought enough vaccine doses to immunize everyone, and that stockpile has come at the expense of other countries.

  • Experts agree no vaccine should be wasted or allowed to expire, and it also may not be logistically feasible for the U.S. to ship some of its surplus doses elsewhere.
  • But variants have become a top concern precisely because of the maldistribution of vaccines.
  • "This virus has proven what most pathogens do: They mutate," said Doug Diekema, a bioethicist and physician at Seattle Children’s Hospital. "The best way to stop that is to stop transmission, and to do that, you have to get as many people vaccinated as possible."

The bottom line: "The Delta variant didn't come from nowhere," Faden said. "To have a better chance of containing this pandemic, we have a self-interested reason in seeing vaccination coverage go up in people outside of our country."

Why the startup world needs to ditch "unicorns" for "dragons"

When Aileen Lee originally coined the term "unicorn" in late 2013, she was describing the 39 "U.S.-based software companies started since 2003 and valued at over $1 billion by public or private market investors."

Flashback: It got redefined in early 2015 by yours truly and Erin Griffith, in a cover story for Fortune, as any privately-held startup valued at $1 billion or more. At the time, we counted 80 of them.

Keep reading... Show less

Scoop: Facebook's new moves to lower News Feed's political volume

Facebook plans to announce that it will de-emphasize political posts and current events content in the News Feed based on negative user feedback, Axios has learned. It also plans to expand tests to limit the amount of political content that people see in their News Feeds to more countries outside of the U.S.

Why it matters: The changes could reduce traffic to some news publishers, particularly companies that post a lot of political content.

Keep reading... Show less

Scoop: Amazon quietly getting into live audio business

Amazon is investing heavily in a new live audio feature that's similar to other live audio offerings like Clubhouse, Twitter Spaces and Spotify's new live audio platform, sources tell Axios.

Why it matters: As with Amazon's efforts in podcasting and music subscriptions, the company sees live audio as a way to bolster the types of content it can offer through its voice assistant, Alexa, and its smart speaker products.

Keep reading... Show less

Hurricane Ida exposes America's precarious energy infrastructure

The powerful hurricane that plunged New Orleans into darkness for what could be weeks is the latest sign that U.S. power systems are not ready for a warmer, more volatile world.

The big picture: “Our current infrastructure is not adequate when it comes to these kinds of weather extremes,” Joshua Rhodes, a University of Texas energy expert, tells Axios.

Keep reading... Show less

"We must go further": 70% of adults in European Union are fully vaccinated

About 70% of adults in the European Union are fully vaccinated against COVID-19, Ursula von der Leyen, the president of the European Commission, said Tuesday.

Why it matters: The milestone makes the E.U. one of the world's leaders in inoculations, after an initially lagging vaccine campaign, the New York Times notes.

Keep reading... Show less

What Elizabeth Holmes jurors will be asked ahead of fraud trial

Jury selection begins today in USA v. Elizabeth Holmes, with the actual jury trial to get underway on Sept. 8.

Why it matters: Theranos was the biggest fraud in Silicon Valley history, putting both hundreds of millions of dollars and thousands of patients' health at risk.

Keep reading... Show less

Insights

mail-copy

Get Goodhumans in your inbox

Most Read

More Stories